絞り込み

17057

広告

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.

著者 D'Angelo SP , Russell J , Lebbé C , Chmielowski B , Gambichler T , Grob JJ , Kiecker F , Rabinowits G , Terheyden P , Zwiener I , Bajars M , Hennessy M , Kaufman HL
JAMA Oncol.2018 Mar 22 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (36view , 0users)

Full Text Sources

Medical

Other Literature Sources

Merkel cell carcinoma (MCC) is an aggressive skin cancer that is associated with poor survival outcomes in patients with distant metastatic disease. Results of part A of the JAVELIN Merkel 200 trial (avelumab in patients with Merkel cell carcinoma) showed that avelumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, demonstrated efficacy in second-line or later treatment of patients with metastatic MCC (mMCC).
PMID: 29566106 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード